actavis.pt Report : Visit Site

Technical data of the actavis.pt

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host actavis.pt. Currently, hosted in Israel and its service provider is TEVA .

the related websites

actavis.co.uk bloomberg.com actavisacademy.co.uk xpil.medicines.org.uk medicines.org.uk mhra.gov.uk ft.com thelawyer.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Microsoft-IIS/8.5 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

-- pharmaceutical industries ltd. teva worldwide stock your browser does not support iframes. contact us hebrew see teva's sites around the world americas canada united states growth markets argentina australia belarus brazil chile china india israel kazakhstan mexico peru russia singapore south africa turkey ukraine uruguay uzbekistan japan & s. korea japan south korea europe europe austria belgium bosnia & herzegovina bulgaria croatia czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania macedonia netherlands norway poland portugal romania serbia slovakia slovenia spain sweden switzerland united kingdom see all see less want to find out more about teva's locations and phone numbers? visit teva worldwide teva deploys 2d barcode to fight counterfeit drugs discover more picture this: ‘our very own teva instagram’ discover more keep on trucking: natural gas fuels distribution discover more connecting people living with ms discover more about about lobby company profile corporate officers corporate governance board of directors our history 2017 annual report – form 10-k quality notice of annual meeting of shareholders 2017 – proxy statement products products lobby specialty generic products generic faq over the counter (otc) api quality central nervous system (cns) respiratory research research lobby integrated r&d; our focus patient promise pipeline national network of excellence responsibility responsibility lobby social impact positions & policies patient advocacy social impact report multiple chronic conditions media media lobby latest news featured stories social media featured stories social media investors investors lobby news webcasts and presentations corporate governance financial information stock information shareholder information analysts coverage/consensus investor kit careers careers lobby dare to be different our guiding values leadership development working at teva dare to be different search teva jobs teva worldwide stock contact us hebrew follow us: teva in action see what we’re doing and where all news top news jun 28, 2018 teva to present new fremanezumab data, including long-term data, at the american headache society’s 60th annual scientific meeting learn more share top news jun 15, 2018 teva provides update on clinical trial of fremanezumab for use in chronic cluster headache learn more share top news may 23, 2018 teva confirms september pdufa date for fremanezumab learn more share top news may 18, 2018 correcting and replacing teva announces publication of phase iii trial data of fremanezumab for the preventive treatment of episodic migraine in the journal of the american medical association learn more share top news may 15, 2018 teva announces publication of phase iii trial data of fremanezumab for the preventive treatment of episodic migraine in the journal of the american medical association learn more share life effects: amplifying the patient voice learn more featured stories take a closer look at what’s happening at teva all featured stories understanding every breath discover more earth day and every day our commitment to acting sustainably and treating the environment with respect learn more meeting the challenge of multiple chronic conditions learn more karaoke encore for parkinson’s patients discover more inside the brand learn more target zero: ehs excellence awards recognizing teams and projects around the globe that enhance our environment, health and safety (ehs). discover more our unique perspective on health enables you to live better days specialized in cns & respiratory cutting-edge r&d uncompromising quality the world’s generic leader corporate responsibility about company profile corporate officers corporate governance board of directors our history products specialty generic products generic faq over the counter (otc) api quality research integrated r&d; our focus patient promise pipeline responsibility social impact positions & policies patient advocacy media latest news featured stories social media investors news webcasts and presentations corporate governance financial information stock information shareholder information analysts coverage/consensus investor kit careers dare to be different our guiding values leadership development working at teva follow teva: legal notes data privacy tapi teva supplier code of conduct sitemap © 2015

URL analysis for actavis.pt

http://www.tevapharm.com/investor_relations/
http://www.tevapharm.com/teva_worldwide/north_america/teva_in_canada/
http://www.tevapharm.com/teva_worldwide/europe/teva_in_greece/
http://www.tevapharm.com/?catid=%7b4609a932-accb-41a0-8a24-26c7d73c74c8%7d
http://www.tevapharm.com/research_development/rd_partnerships/nne/
http://www.tevapharm.com/about/
http://www.tevapharm.com/?catid=%7b1c22c77d-41b3-4963-aa20-dc955443bb3a%7d
http://www.tevapharm.com/our_products/generic_qa/
http://www.tevapharm.com/files/about/teva_form_10-k-2017.pdf
http://www.tevapharm.com/research_development/rd_integrated/specialty/
http://www.linkedin.com/sharearticle?mini=true&url=http://www.tevapharm.com/news/teva_announces_publication_of_phase_iii_trial_data_of_fremanezumab_for_the_preventive_treatment_of_episodic_migraine_in_the_journal_of_the_american_medical_association_05_18.aspx
http://www.linkedin.com/sharearticle?mini=true&url=http://www.tevapharm.com/news/teva_provides_update_on_clinical_trial_of_fremanezumab_for_use_in_chronic_cluster_headache_06_18.aspx
http://www.tevapharm.com/picture_this_our_very_own_teva_instagram/
http://www.facebook.com/sharer.php?u=http://www.tevapharm.com/news/teva_confirms_september_pdufa_date_for_fremanezumab_05_18.aspx
http://www.tevapharm.com/teva_worldwide/international_markets/australia/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Nome de domínio / Domain Name: actavis.pt
Data de registo / Creation Date (dd/mm/yyyy): 30/01/2006
Data de expiração / Expiration Date (dd/mm/yyyy): 28/02/2018
Estado / Status: ACTIVE

Titular / Registrant
Actavis Group hf.
Reykjavikurvegi 76-78
Hafnarfjordur
220 Hafnarfjordur
Email: [email protected]

Entidade Gestora / Billing Contact
MarkMonitor Inc.
Email: [email protected]

Responsável Técnico / Tech Contact
MarkMonitor Inc.
Email: [email protected]

Nameserver Information
Nameserver: actavis.pt NS andromeda.medis.is.
Nameserver: actavis.pt NS odinn.medis.is.

  REFERRER http://www.fccn.pt

  REGISTRAR FCCN

SERVERS

  SERVER pt.whois-servers.net

  ARGS actavis.pt

  PORT 43

  TYPE domain

DOMAIN

  NAME actavis.pt

  CREATED 2006-01-30

  STATUS ACTIVE

NSERVER

  ACTAVIS.PT 192.115.248.118

OWNER

  EMAIL [email protected]

  NAME Actavis Group hf.

ADDRESS
Reykjavikurvegi 76-78
Hafnarfjordur
220 Hafnarfjordur

BILLING

  EMAIL [email protected]

  NAME MarkMonitor Inc.

ADDRESS
Responsável Técnico / Tech Contact
MarkMonitor Inc.

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .